目次

Table of Contents

Executive Summary

Market Overview

Market Landscape
Market ecosystem
Value chain analysis

Market Sizing
Market definition
Market segment analysis
Market size 2020
Market outlook: Forecast for 2020 - 2025

Five Forces Analysis
Five forces analysis
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition

Market Segmentation by Product
Market segments
Comparison by Product
Artemisinin compounds - Market size and forecast 2020-2025
Quinolines and related compounds - Market size and forecast 2020-2025
Other compounds - Market size and forecast 2020-2025
Market opportunity by Product

Customer landscape

Geographic Landscape
Geographic segmentation
Geographic comparison
Asia - Market size and forecast 2020-2025
ROW - Market size and forecast 2020-2025
Europe - Market size and forecast 2020-2025
North America - Market size and forecast 2020-2025
Key leading countries
Market opportunity by geography
Market drivers
Market challenges
Market trends

Vendor Landscape
Vendor landscape
Landscape disruption

Vendor Analysis
Vendors covered
Market positioning of vendors
AstraZeneca Plc
Bayer AG
Cipla Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Mylan NV
Novartis AG
Pfizer Inc.
Sanofi SA
Sun Pharmaceutical Industries Ltd.

Appendix
Scope of the report
Currency conversion rates for US$
Research methodology
List of abbreviations

Exhibits
1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2020 - 2025 ($ million)
13: Global market: Year-over-year growth 2020 - 2025 (%)
14: Five forces analysis 2020 & 2025
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2020
21: Product - Market share 2020-2025 (%)
22: Comparison by Product
23: Artemisinin compounds - Market size and forecast 2020-2025 ($ million)
24: Artemisinin compounds - Year-over-year growth 2020-2025 (%)
25: Quinolines and related compounds - Market size and forecast 2020-2025 ($ million)
26: Quinolines and related compounds - Year-over-year growth 2020-2025 (%)
27: Other compounds - Market size and forecast 2020-2025 ($ million)
28: Other compounds - Year-over-year growth 2020-2025 (%)
29: Market opportunity by Product
30: Customer landscape
31: Market share by geography 2020-2025 (%)
32: Geographic comparison
33: Asia - Market size and forecast 2020-2025 ($ million)
34: Asia - Year-over-year growth 2020-2025 (%)
35: ROW - Market size and forecast 2020-2025 ($ million)
36: ROW - Year-over-year growth 2020-2025 (%)
37: Europe - Market size and forecast 2020-2025 ($ million)
38: Europe - Year-over-year growth 2020-2025 (%)
39: North America - Market size and forecast 2020-2025 ($ million)
40: North America - Year-over-year growth 2020-2025 (%)
41: Key leading countries
42: Market opportunity by geography ($ million)
43: Impact of drivers and challenges
44: Vendor landscape
45: Landscape disruption
46: Industry risks
47: Vendors covered
48: Market positioning of vendors
49: AstraZeneca Plc - Overview
50: AstraZeneca Plc - Product and service
51: AstraZeneca Plc - Key offerings
52: AstraZeneca Plc - Key customers
53: AstraZeneca Plc - Segment focus
54: Bayer AG - Overview
55: Bayer AG - Business segments
56: Bayer AG - Key offerings
57: Bayer AG - Key customers
58: Bayer AG - Segment focus
59: Cipla Inc. - Overview
60: Cipla Inc. - Business segments
61: Cipla Inc. - Key offerings
62: Cipla Inc. - Key customers
63: Cipla Inc. - Segment focus
64: F. Hoffmann-La Roche Ltd. - Overview
65: F. Hoffmann-La Roche Ltd. - Business segments
66: F. Hoffmann-La Roche Ltd. - Key offerings
67: F. Hoffmann-La Roche Ltd. - Key customers
68: F. Hoffmann-La Roche Ltd. - Segment focus
69: GlaxoSmithKline Plc - Overview
70: GlaxoSmithKline Plc - Business segments
71: GlaxoSmithKline Plc - Key offerings
72: GlaxoSmithKline Plc - Key customers
73: GlaxoSmithKline Plc - Segment focus
74: Mylan NV - Overview
75: Mylan NV - Business segments
76: Mylan NV - Key offerings
77: Mylan NV - Key customers
78: Mylan NV - Segment focus
79: Novartis AG - Overview
80: Novartis AG - Business segments
81: Novartis AG - Key offerings
82: Novartis AG - Key customers
83: Novartis AG - Segment focus
84: Pfizer Inc. - Overview
85: Pfizer Inc. - Business segments
86: Pfizer Inc. - Key offerings
87: Pfizer Inc. - Key customers
88: Pfizer Inc. - Segment focus
89: Sanofi SA - Overview
90: Sanofi SA - Business segments
91: Sanofi SA - Key offerings
92: Sanofi SA - Key customers
93: Sanofi SA - Segment focus
94: Sun Pharmaceutical Industries Ltd. - Overview
95: Sun Pharmaceutical Industries Ltd. - Business segments
96: Sun Pharmaceutical Industries Ltd. - Key offerings
97: Sun Pharmaceutical Industries Ltd. - Key customers
98: Sun Pharmaceutical Industries Ltd. - Segment focus
99: Currency conversion rates for US$
100: Research Methodology
101: Validation techniques employed for market sizing
102: Information sources
103: List of abbreviations